No Photo Available

Last Update

2015-09-14T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong David Enscore?

Dr. David J. Enscore PhD

Vice President, Research, Development and Drug Delivery

Focal , Incorporated

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Focal , Incorporated

Background Information

Employment History

Senior Vice President of Research and Development

Altea Therapeutics Corporation

Named Interim President

Spherics , Inc.

Education

BS

North Carolina State University

Ph.D.

PhD

Chemical Engineering

North Carolina State University

Web References (26 Total References)


Leadership - 4P THERAPEUTICS - Transdermal Research and Development

www.4ptherapeutics.com [cached]

David Enscore, Ph.D. - Principal Scientist

David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent.
He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants.
Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


David Enscore, ...

www.4ptherapeutics.com [cached]

David Enscore, Ph.D. Senior Scientific Advisor

David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent. He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants. Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


Altea Therapeutics Appoints Senior R&D Executive Dr. David J. Enscore to Lead Product Development

biz.yahoo.com [cached]

Altea Therapeutics Appoints Senior R&D Executive Dr. David J. Enscore to Lead Product DevelopmentAltea Therapeutics Appoints Senior R&D Executive Dr. David J. Enscore to Lead Product Development

...
Altea Therapeutics Appoints Senior R&D Executive Dr. David J. Enscore to Lead Product Development
...
TUCKER, Ga.--(BUSINESS WIRE)--Dec. 11, 2003--Altea Therapeutics has appointed David J. Enscore, PhD, as Senior Vice President for Product Research & Development.Dr. Enscore is responsible for leading all of the Company's pharmaceutical product research and development activities.The Company's lead clinical products are a daily insulin skin patch for treating individuals with diabetes and a hydromorphone skin patch for the controllable management of severe acute and chronic pain.
David Enscore has had an extensive career in the development of novel therapeutic products.He was previously at ALZA as Executive Director, Transdermal Product Development where he managed the development of four commercial controlled release pharmaceuticals, including NICODERM CQ (Transdermal Nicotine).More recently he was Vice President for Research & Development at Focal, Inc., responsible for the definition, development and market introduction of two surgical sealant products: FocalSeal-L and FocalSeal-S.He joins Altea Therapeutics from Spherics, Inc., a drug delivery company based in Lincoln, RI, where was President and Head of Research & Development.Dr. Enscore is an Inventor on 24 U.S. patents in drug delivery and medical devices.
"David's appointment will strengthen both our pharmaceutical development capabilities and our project management needs as we transition from a technology-based company to one developing high-value pharmaceutical products" said Eric Tomlinson, D.Sc., Ph.D., the Company's Chief Executive Officer."
...
It offers a painless alternative to needle injections while providing controllable drug delivery," said Dr. Enscore.


Todays News

www.prnewswire.com [cached]

David J. Enscore, Ph.D. Joins Spherics, Inc. as Vice President, Research and Development

Former Alza Corp.Executive to Lead Research and Development Team.
WARWICK, R.I., Sept. 21 /PRNewswire / -- Spherics, Inc., a company applying bioadhesive technologies to develop oral formulations of biopharmaceuticals and poorly absorbed small molecule drugs today announced the appointment of David J. Enscore, Ph.D. as Vice President, Research and Development.Dr. Enscore, formerly of Alza Corporation and Focal, Inc., has over 18 years experience in drug delivery research.
...
Dr. Enscore has over 18 years experience in drug delivery at Alza Corporation and most recently, as Vice President, Research and Development at Focal Inc., in Lexington, MA.At Focal, he led all activities surrounding core polymer technologies for Formulation, Clinical and Commercial Synthesis Process Development, Clinical and Commercial Sterile Process Development, Analytical Chemistry, Product Stability, and Drug Delivery.Dr. Enscore grew Focal Inc.'s research and development group from 12 to 40 employees and directed the definition, development and commercialization of two surgical sealant products comprising three new molecular entity polymeric materials.
As Executive Director, Transdermal Product Development, among other executive and management positions he held at Alza Corporation, Dr. Enscore was responsible for the development of four commercial controlled release pharmaceuticals, including NICODERM CQ.
Spherics is developing proprietary drug delivery technologies to improve the oral delivery of small molecule drugs that are poorly absorbed from the gastrointestinal (GI) tract and to enable the oral delivery of proteins, peptides, and oligonucleotides (including DNA for gene therapy) that at present must be given by injection.


About Altea Therapeutics

www.alteatherapeutics.com [cached]

David EnscoreSenior Vice PresidentProduct Research & Development

Similar Profiles

Other People with this Name

Other people with the name Enscore

Johnny Enscore
Builders FirstSource, Inc.

Kelly Enscore
Thomson Reuters Corporation

Susan Enscore
Army Corps

Michael Enscore
Home Builders Association of Winston-Salem Inc

Emory Enscore
Kecoughtan High School

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory